1-4 of 4
Pei-Ching Hsiao, MD
Close
Sort by
Journal Articles

NOVEL-1 st : A Non-Interventional, Multi-Center Observational Study to Assess the Safety and Efficacy of Nilotinib in Newly Diagnosed Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) in Taiwan

Hwang Wen-Li, MD, Tsung-Chih Chen, MD, Shyuann-Yuh Lin, MD, Ming-Chih Chang, MD, Pei-Ching Hsiao, MD, Li-Yuan Bai, PhD, Ching-Yuan Kuo, Yeu-Chin Chen, MD, Ta-Chih Liu, MD PhD, Jyh-Pyng Gau, MD, Po-Nan Wang, MD, Chieh-Wen Chen, Yee-Ming Lee, PhD, Fan-Chen Ku, MD, Jih-Luh Tang, MD, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-137327
Published: 2020
Journal Articles

NOVEL-1 st : Interim Analysis of a Non-Interventional, Multi-Center Observational Study to Assess the Safety and Efficacy of Nilotinib in Newly Diagnosed Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) in Taiwan

Hwang Wen-Li, MD, Shao-Min Han, MD, Shyuann-Yuh Lin, MD, Ming-Chih Chang, MD, Li-Yuan Bai, PhD, Pei-Ching Hsiao, MD, Ching-Yuan Kuo, Yeu-Chin Chen, MD, Ta-Chih Liu, MD PhD, Po-Nan Wang, MD, Jyh-Pyng Gau, MD, Yee-Ming Lee, PhD, Fan-Chen Ku, Jih-Luh Tang, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3019.
https://doi.org/10.1182/blood-2018-99-112342
Published: 2018
Journal Articles

Comparison of Molecular Responses between e14a2 and e13a2 BCR-ABL1 Transcripts in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Front-Line Second Generation Tyrosine Kinase Inhibitors: Taiwan CML Study

Yi-Jiun Su, MD, Ming-Chung Kuo, MD, Chieh-Lin Teng, MD, Tsai-Yun Chen, MD, Ming-Chun Ma, MD, Pei-Ching Hsiao, MD, Ming-Chung Wang, MD, Tung-Huei Lin, MS, Wen-Li Hwang, MD, Chih-Cheng Chen, MD, Youngsen Yang, MD, Sung-Nan Pei, MD, Yen-Min Huang, MD, Sin-Syue Li, MD, Ming-Yang Lee, MD, Hung-I Cheng, MD, Lee-Yung Shih, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1603.
https://doi.org/10.1182/blood.V130.Suppl_1.1603.1603
Published: 2017
Journal Articles

No Differences in Outcomes Between Patients Achieving Early Molecular Response at 3 Months and Those Achieving Optimal Response at 6 or 12 Months in Chronic Phase of Chronic Myeloid Leukemia Treated with Front-Line Imatinib: Taiwan CML Study

Ming-Chung Kuo, MD, Tsai-Yun Chen, MD, Ming-Chung Wang, MD, Youngsen Yang, MD, Su-Peng Yeh, MD, Cheng-Shyong Chang, MD, Yii-Jenq Lan, MD, Chih-Cheng Chen, MD, Yu-Chieh Su, MD, Pei-Ching Hsiao, MD, Ching-Yuan Kuo, MD, Li-Yuan Bai, MD, Wen-Li Hwang, MD, Lee-Yung Shih, MD
Journal: Blood
Blood (2014) 124 (21): 4544.
https://doi.org/10.1182/blood.V124.21.4544.4544
Published: 2014